This article is more than 5 years old. Information may no longer be current.

FDA approves Lucentis prefilled syringe

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Genentech’s pre-filled Lucentis (ranibizumab injection) syringe has been approved by the FDA, the company announced.

The 0.5 mg prefilled syringe was approved to treat patients with wet age-related macular degeneration and macular edema after retinal vein occlusion and is the first pre-filled anti-VEGF medication to be approved by the FDA, the announcement said.

“With the PFS, physicians will have a new option for administering Lucentis to the hundreds of thousands of people in the U.S. diagnosed with either wet AMD or macular edema after RVO,” Sandra Horning, MD, chief medical officer and head of global product development at Genentech said.

The pre-filled Lucentis syringe is expected to be available in early 2017.